| Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology JD Salamone, SE Yohn, L López-Cruz, N San Miguel, M Correa Brain 139 (5), 1325-1347, 2016 | 332 | 2016 |
| Mesolimbic dopamine and the regulation of motivated behavior JD Salamone, M Pardo, SE Yohn, L López-Cruz, N SanMiguel, M Correa Behavioral neuroscience of motivation, 231-257, 2016 | 224 | 2016 |
| The behavioral neuroscience of motivation: an overview of concepts, measures, and translational applications EH Simpson, PD Balsam Behavioral neuroscience of motivation, 1-12, 2016 | 174 | 2016 |
| Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression EJ Nunes, PA Randall, EE Hart, C Freeland, SE Yohn, Y Baqi, CE Müller, ... Journal of Neuroscience 33 (49), 19120-19130, 2013 | 138 | 2013 |
| The pharmacology of effort-related choice behavior: Dopamine, depression, and individual differences JD Salamone, M Correa, S Yohn, LL Cruz, N San Miguel, L Alatorre Behavioural Processes 127, 3-17, 2016 | 132 | 2016 |
| Bupropion increases selection of high effort activity in rats tested on a progressive ratio/chow feeding choice procedure: implications for treatment of effort-related … PA Randall, CA Lee, SJ Podurgiel, E Hart, SE Yohn, M Jones, M Rowland, ... International Journal of Neuropsychopharmacology 18 (2), pyu017, 2015 | 110 | 2015 |
| The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs PA Randall, CA Lee, EJ Nunes, SE Yohn, V Nowak, B Khan, P Shah, ... PloS one 9 (6), e99320, 2014 | 105 | 2014 |
| The role of dopamine D1 receptor transmission in effort-related choice behavior: effects of D1 agonists SE Yohn, JL Santerre, EJ Nunes, R Kozak, SJ Podurgiel, M Correa, ... Pharmacology Biochemistry and Behavior 135, 217-226, 2015 | 95 | 2015 |
| The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A 2A antagonist MSX-3 and … SE Yohn, C Thompson, PA Randall, CA Lee, CE Müller, Y Baqi, M Correa, ... Psychopharmacology 232, 1313-1323, 2015 | 92 | 2015 |
| Not all antidepressants are created equal: differential effects of monoamine uptake inhibitors on effort-related choice behavior SE Yohn, SL Collins, HM Contreras-Mora, EL Errante, MA Rowland, ... Neuropsychopharmacology 41 (3), 686-694, 2016 | 90 | 2016 |
| Blockade of uptake for dopamine, but not norepinephrine or 5-HT, increases selection of high effort instrumental activity: implications for treatment of effort-related … SE Yohn, EE Errante, A Rosenbloom-Snow, M Somerville, M Rowland, ... Neuropharmacology 109, 270-280, 2016 | 78 | 2016 |
| Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization SE Yohn, Y Arif, A Haley, G Tripodi, Y Baqi, CE Müller, NS Miguel, ... Psychopharmacology 233, 3575-3586, 2016 | 77 | 2016 |
| Effects of lisdexamfetamine and s-citalopram, alone and in combination, on effort-related choice behavior in the rat SE Yohn, L Lopez-Cruz, PH Hutson, M Correa, JD Salamone Psychopharmacology 233, 949-960, 2016 | 75 | 2016 |
| Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia SE Yohn, PJ Conn Neuropharmacology 136, 438-448, 2018 | 58 | 2018 |
| Cholinergic projections to the substantia nigra pars reticulata inhibit dopamine modulation of basal ganglia through the M4 muscarinic receptor MS Moehle, T Pancani, N Byun, SE Yohn, GH Wilson, JW Dickerson, ... Neuron 96 (6), 1358-1372. e4, 2017 | 54 | 2017 |
| Chronic corticosterone administration induces negative valence and impairs positive valence behaviors in mice A Dieterich, P Srivastava, A Sharif, K Stech, J Floeder, SE Yohn, ... Translational psychiatry 9 (1), 337, 2019 | 49 | 2019 |
| Evaluation of the effort-related motivational effects of the novel dopamine uptake inhibitor PRX-14040 SE Yohn, A Gogoj, A Haque, L Lopez-Cruz, A Haley, P Huxley, P Baskin, ... Pharmacology Biochemistry and Behavior 148, 84-91, 2016 | 48 | 2016 |
| Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia SM Paul, SE Yohn, M Popiolek, AC Miller, CC Felder American Journal of Psychiatry 179 (9), 611-627, 2022 | 37 | 2022 |
| Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators SE Yohn, DJ Foster, DP Covey, MS Moehle, J Galbraith, ... Molecular psychiatry 25 (11), 2786-2799, 2020 | 33 | 2020 |
| Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic SE Yohn, PJ Weiden, CC Felder, SM Stahl Trends in Pharmacological Sciences 43 (12), 1098-1112, 2022 | 32 | 2022 |
